A Faster Track from Knowledge to Clinical Use

Thanks to a bigger push for innovation as part of the End TB strategy, new medicines—bedaquiline (Sirturo™) and delamanid (Deltyba™)—are now available to treat MDR-TB and XDR-TB with a novel short-course regimen.

However, countries and partners have been slow to use these drugs, and many health workers lack expertise in prescribing them. Many health facilities also lack a system to monitor the efficacy, safety, and potential adverse effects of these medicines. To increase the use of these new treatments and boost good health outcomes, it is critical to share accurate and reliable information about their appropriate management and safe use.

Experts in MDR-TB have already been teaching these innovations to health care workers at in-person workshops organized by the US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program in collaboration with national TB programs and partner organizations. SIAPS has trained hundreds of people in five countries over the past 18 months.

Now, there is a new, easier, and faster way to learn about these innovations in TB treatment: An online course. Participants can access comprehensive information about the new medicines and regimens at any time and at no cost. The online course was developed by SIAPS and implemented by Management Sciences for Health (MSH) with financial support from USAID to help low- and middle-income countries adopt new TB medicines and regimens more quickly.

USAID
FROM THE AMERICAN PEOPLE

SIAPS
Systems for Improved Access to Pharmaceuticals and Services

Tel: +1 (703) 524-6575

E-mail: siaps@msh.org
Web: www.siapsprogram.org

4301 N. Fairfax Drive, Suite 400
Arlington, VA 22203 USA

LeaderNet
STRONGER LEADERS. STRONGER HEALTH SYSTEMS.

INTRODUCING

Using New TB Medicines & Regimens eCourse

Learn about the new medicines and treatment regimens for multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) with a free, self-paced, and interactive course.

New Medicines eCOURSE

A New eCourse on leadernet.org available November 2016

Course Benefits

- Easy to use
- Self-paced and self-directed
- 24-hour access
- **Free of charge**
- A central repository for documents related to new TB medicines, including World Health Organization publications
- Clinical resources, job aids, sample forms, and frequently asked questions for quick and easy access to information
- An interactive learning environment featuring practical case studies

Course Content

The web-based eight-module course is based on current global recommendations and the End TB strategy. Participants can review all modules or choose specific topics of interest and can download clinical resources for further study. Topics include:

- An introduction to the new medicines and current treatment guidelines
  - o Detailed information about the use of bedaquiline and delamanid
  - o Detailed information about the nine-month regimen
- Clinical management resources for the new medicines, including:
  - o Treatment algorithms
  - o Regimen design
  - o Use of TB medicines in special populations (TB/HIV co-infected patients, pregnant/breastfeeding women, and pediatric patients)
  - o Sample informed consent forms
- Recommendations for recording and reporting information about patients on new TB medicines and regimens
- Managing patients and monitoring adverse events
- Ethical considerations
- Pharmacovigilance

Who should take this course?

The eCourse will inform health care workers involved with prescribing and managing new TB medicines and regimens, including:

- Doctors
- Nurses
- Pharmacists
- Health leaders
  - o national TB program staff
  - o implementing partners
  - o high-level decision makers
  - o monitoring and evaluation professionals may benefit from the modules on tracking treatment and outcomes

How to Enroll

Using New TB Medicines & Regimens eCourse is coming to **leadernet.org** in November 2016.

Pre-register at the MSH booth with your name and email address in order to receive a link for the course in November 2016

For more about SIAPS activities related to introducing new TB medicines and regimens, **go to NewTBdruginfo.org.**